Bevacizumab as adjuvant therapy in the management of pterygium: a systematic review and Meta-analysis |
| |
Authors: | Jian Liu Jie-Hui Xu Wen Xu Guan-Lu Liang Ji-Xian Lou Yi Wang Ji-Quan Wen and Yong-Bao Cao |
| |
Institution: | Department of Ophthalmology, Zhejiang Hospital, Hangzhou 310012, Zhejiang Province, China,Department of Ophthalmology, Zhejiang Hospital, Hangzhou 310012, Zhejiang Province, China,Eye Center, the Second Affiliated Hospital of Zhejiang University, College of Medicine, Hangzhou 310009, Zhejiang Province, China,Department of Ophthalmology, Zhejiang Hospital, Hangzhou 310012, Zhejiang Province, China,Department of Ophthalmology, Zhejiang Hospital, Hangzhou 310012, Zhejiang Province, China,Department of Ophthalmology, Zhejiang Hospital, Hangzhou 310012, Zhejiang Province, China,Department of Ophthalmology, Zhejiang Hospital, Hangzhou 310012, Zhejiang Province, China and Department of Ophthalmology, Zhejiang Hospital, Hangzhou 310012, Zhejiang Province, China |
| |
Abstract: | AIM: To evaluate the clinical effect of bevacizumab in pterygium treatment.
METHODS: A systematic review and quantitative Meta-analysis was performed. PubMed, EMBASE, Web of Science and Cochrane database were searched for eligible literatures published in English until June 2016. The endpoint was recurrence rate and pooled risk ratio (RR) was calculated.
RESULTS: Nine eligible studies were included and Meta-analysis results showed no significantly difference in patients treated with bevacizumab in short term follow-up 3mo: RR=0.70 (0.34, 1.45); 6mo: RR=0.55 (0.23, 1.32)] compared with control groups. No significant effects were observed in favor of bevacizumab in subgroup analyses: patients with subconjunctival injection of bevacizumab 3mo: RR=0.95 (0.70, 1.29); 6mo: RR=0.83 (0.55, 1.28)], primary pterygium 3mo: RR=0.59 (0.23, 1.54; 6mo: RR=0.59 (0.23, 1.53)], simple pterygium excision 3mo: 0.32 (0.05, 2.04), P=0.23; 6mo: 0.27 (0.05, 1.53)] and excision with conjunctival autograft 3mo: 1.51 (0.25, 9.15); 6mo: 1.11 (0.06, 21.69)].
CONCLUSION: In this Meta-analysis, we did not found the significant effect of bevacizumab in pterygium treatment, at least in short term follow-up (3mo and 6mo). |
| |
Keywords: | pterygium bevacizumab therapy recurrence Meta-analysis |
|
| 点击此处可从《国际眼科杂志(英文版)》浏览原始摘要信息 |
| 点击此处可从《国际眼科杂志(英文版)》下载免费的PDF全文 |
|